<DOC>
	<DOCNO>NCT00006372</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetic profile gemcitabine , doxorubicin HCl liposome , vinorelbine patient advance solid tumor . - Determine maximum tolerate dose regimen patient . - Determine toxicity profile regimen patient . OUTLINE : This dose escalation study . Patients receive doxorubicin HCl liposome IV 1-2.5 hour day 1 , gemcitabine IV 30 minute day 1 8 , vinorelbine IV 6-10 minute day 1 15 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome , gemcitabine , vinorelbine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : Approximately 9-24 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor amenable curative surgery , radiotherapy , chemotherapy No brain metastases primary brain tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 1.2 mg/dL AST and/or ALT le 2.5 time upper limit normal ( ULN ) PT great ULN ( anticoagulant independent ) Renal : Creatinine great 1.5 mg/dL AND/OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease LVEF least 45 % MUGA echocardiogram Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell transplantation follow high dose chemotherapy At least 3 week since prior biologic therapy cancer recover No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy : See Disease Characteristics See Biologic therapy No 1 prior chemotherapy regimen No prior vinca alkaloid Prior anthracycline allow total dose great 300 mg/m2 At least 3 week since prior chemotherapy ( 6 week mitomycin carmustine ) recover Endocrine therapy : At least 3 week since prior endocrine therapy cancer recover Radiotherapy : See Disease Characteristics No 1 prior radiotherapy regimen At least 4 week since prior large field radiotherapy At least 3 week since prior radiotherapy cancer recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>